GenAIz empowers pharmaceutical and life sciences organizations to unlock the value of their data by connecting systems and applying AI—so teams can act with clarity, confidence, and speed.
Just like a conductor brings harmony to an orchestra, our AI platform brings order to complex data landscapes. GenAIz harmonizes your diverse data sources, providing actionable insights that accelerate the path from lab to market.
Our suite of intelligent tools helps life sciences organizations reduce delays, improve accuracy, and get therapies to patients faster—while staying fully compliant.
Our Intelligent Solutions are built from the ground up to comply with GxP standards, ensuring that your processes meet rigorous regulatory expectations while improving:













Access the power of AI in just three clicks—no technical background required.
Engineered for precision. Built to deliver trustworthy insights without the complexity.
Connect and analyze data across any format, structure, or location—Word, Excel, SharePoint, Google Drive, Amazon S3, RegDocs365, and more.
From a single document to millions of data points, GenAIz delivers lightning-fast processing—up to 100,000 words per second and 120x faster reviews.
Free up your teams to focus on high-impact work. GenAIz automates high-volume, repetitive, or complex tasks with a growing portfolio of plug-and-play solutions:
From system architecture to legal frameworks, we designed GenAIz to protect your ownership—your data, your models, and the insights they generate.
We approach AI development with care—prioritizing fairness, minimizing bias, and aligning with ethical standards.
Our data mesh infrastructure ensures your data stays in your environment—always.
Deploy securely with single-tenant architecture—on your preferred cloud or on-premises.
CellCarta, a global leader in immune monitoring for clinical trials, partnered with GenAIz to automate the T Cell Health Index—an innovative analysis service designed to assess immune response in early-stage drug development.
Their goal? Use AI to generate enough clinical evidence during Phase 2 trials to potentially bypass Phase 3—dramatically accelerating timelines to get life-changing therapies to patients faster.
To achieve this, GenAIz helped CellCarta address three major bottlenecks:
The manual process was complex, unscalable, and human-dependent. With GenAIz, CellCarta automated this pipeline using:
This collaboration marks a major leap toward scalable, AI-powered clinical trial innovation.
Headquartered in Montreal, GenAIz is led by industry veterans with deep expertise in AI, regulatory compliance, and life sciences.